Senores Pharmaceuticals IPO Review & Recommendations

Senores Pharmaceuticals IPO Peer Comparison

Senores Pharmaceuticals Limited peer comparison with similar listed entities. (As on March 28, 2024)

Source: All the financial information for the listed industry peers mentioned above is consolidated and sourced from the filings made with stock exchanges for Fiscal 2024. Source for the Company: Based on the Restated Consolidated Financial Information for the six months ended September 30, 2024.

Notes:

1. The P/E Ratio has been computed based on the closing market price of equity shares on December 13, 2024, divided by the Diluted EPS.
2. Return on Net Worth (%) = Net profit after tax, as restated / Average shareholders' equity (including minority interest) as restated at year/period end.
3. NAV is computed as the closing net worth (excluding minority interest) divided by the closing outstanding number of equity shares.
4. Net worth means the aggregate value of the paid-up share capital of the Company and all reserves created out of profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, miscellaneous expenditure not written off, as per the restated balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation as at year/ period end, as per Restated Financial Statement of Assets and Liabilities of the Company.